Tobramycin EQL Pharma (Tobramycin)

What Is Tobramycin EQL Pharma and What Is It Used For?

Tobramycin is a bactericidal antibiotic that belongs to the aminoglycoside class, a group that also includes gentamicin, amikacin, streptomycin, and netilmicin. First isolated in 1967 from the actinomycete Streptomyces tenebrarius, tobramycin was introduced into clinical use in the 1970s and remains one of the most important agents for treating infections caused by multidrug-resistant gram-negative pathogens. Tobramycin EQL Pharma is a generic preparation supplied as a clear, colorless to pale yellow aqueous solution in a concentration of 40 mg of tobramycin (as tobramycin sulfate) per millilitre, intended for intravenous infusion or intramuscular injection.

Mechanistically, tobramycin binds irreversibly to the 30S subunit of the bacterial ribosome, specifically to the A-site of the 16S ribosomal RNA. This binding causes misreading of messenger RNA, generates non-functional proteins, destabilises the bacterial cell membrane, and ultimately results in rapid bacterial cell death. Unlike most antibiotics, aminoglycosides exhibit concentration-dependent killing: the higher the peak concentration relative to the minimum inhibitory concentration (MIC) of the organism, the faster and more complete the killing. They also demonstrate a prolonged post-antibiotic effect, continuing to suppress bacterial regrowth for several hours after serum concentrations have fallen below the MIC. These pharmacodynamic properties underpin the modern preference for extended-interval (once-daily) dosing in most patients.

Tobramycin’s spectrum of activity is predominantly against aerobic gram-negative bacilli, including Pseudomonas aeruginosa, Escherichia coli, Klebsiella species, Enterobacter, Serratia marcescens, Proteus species, Citrobacter, Acinetobacter, and Morganella morganii. It is often more active than gentamicin against Pseudomonas aeruginosa, which is one reason it is frequently chosen for severe pseudomonal infections and for patients with cystic fibrosis. Tobramycin has limited activity against most gram-positive organisms when used alone; however, when combined with a cell-wall active agent such as a penicillin or a glycopeptide (vancomycin), it produces useful synergy against enterococci, viridans streptococci, and Staphylococcus aureus, making it a cornerstone of combination regimens for infective endocarditis. Anaerobic bacteria are intrinsically resistant because aminoglycoside uptake into the bacterial cell requires oxygen-dependent active transport.

Approved Indications

Parenteral tobramycin is authorised for the treatment of serious infections, particularly those caused by susceptible strains of aerobic gram-negative bacteria. Typical clinical situations in which tobramycin is used include:

• Septicemia (bloodstream infection), including neonatal sepsis and sepsis of unknown source in critically ill patients, usually in combination with a beta-lactam antibiotic.
• Lower respiratory tract infections, including hospital-acquired pneumonia, ventilator-associated pneumonia, and severe community-acquired pneumonia when gram-negative pathogens are likely or documented.
• Pulmonary exacerbations of cystic fibrosis caused by Pseudomonas aeruginosa, typically in combination with a broad-spectrum anti-pseudomonal beta-lactam (piperacillin-tazobactam, ceftazidime, meropenem).
• Complicated urinary tract infections and acute pyelonephritis, especially when caused by resistant gram-negative organisms.
• Intra-abdominal infections, including peritonitis and post-surgical abdominal sepsis.
• Skin, soft tissue, bone, and joint infections caused by susceptible organisms, such as osteomyelitis and septic arthritis.
• Bacterial meningitis and other central nervous system infections, sometimes administered by intraventricular or intrathecal route under specialist supervision, because systemic tobramycin penetrates the blood-brain barrier poorly.
• Infective endocarditis, in combination therapy with a beta-lactam or vancomycin, typically for enterococcal or streptococcal endocarditis.
• Severe otitis externa, burns complicated by sepsis, and post-operative infections where a gram-negative pathogen is known or strongly suspected.

Because of the risk of toxicity and the selective pressure that promotes resistance, tobramycin is not usually recommended as initial empirical therapy for uncomplicated infections or infections where a safer, equally effective alternative is available. National and international antibiotic stewardship guidelines (such as those from the Infectious Diseases Society of America, the European Society of Clinical Microbiology and Infectious Diseases, and the British National Formulary) emphasise that aminoglycosides should be reserved for severe, documented or highly probable gram-negative infections and that their duration should usually be limited to the shortest effective course.

The choice of tobramycin over gentamicin or amikacin in a given patient depends on local resistance patterns, the pathogen’s susceptibility profile, the clinical context (for example, cystic fibrosis favours tobramycin), and the patient’s renal and auditory function. Susceptibility testing of the isolated organism should guide definitive therapy whenever possible, and empirical tobramycin should be reassessed and de-escalated once culture and sensitivity results are available.

What Should You Know Before Taking Tobramycin EQL Pharma?

Contraindications

Tobramycin EQL Pharma must not be used in patients with:

• Known hypersensitivity (allergy) to tobramycin, to other aminoglycosides (gentamicin, amikacin, streptomycin, netilmicin, neomycin, kanamycin), or to any of the excipients in the formulation. Aminoglycosides share substantial cross-reactivity, and a severe reaction to one should be regarded as a contraindication to the whole class unless alternative therapy is genuinely impossible.
• Severe pre-existing aminoglycoside-induced hearing or vestibular damage that would be worsened by further exposure, unless the benefit clearly outweighs the risk of irreversible deafness.

Relative contraindications that require specialist assessment include severe renal impairment, pregnancy (especially the second and third trimesters), myasthenia gravis, parkinsonism, and other conditions of abnormal neuromuscular transmission.

Warnings and Precautions

Before initiating therapy, the prescriber should assess baseline serum creatinine and estimated glomerular filtration rate (eGFR), body weight (ideal and actual), audiometry when feasible, and a careful medication history to identify concurrent nephrotoxic or ototoxic drugs. During therapy, renal function should typically be rechecked every 2 to 3 days in unstable patients and at least weekly in stable patients, and serum tobramycin levels should be measured according to the dosing regimen (see Dosage section).

Specific Patient Groups Requiring Extra Caution

• Older adults (65+ years): Age-related reductions in glomerular filtration and cochlear function increase the risk of both nephrotoxicity and ototoxicity. Doses should be individualised to measured or estimated renal function, and drug levels should be checked promptly.
• Patients with chronic kidney disease or acute kidney injury: Dose reduction and/or extended dosing intervals are required. In severe impairment, alternative antibiotics are often preferred.
• Patients with dehydration, hypovolemia, or hypotension: Reduced renal perfusion increases drug accumulation in renal tubular cells and worsens the risk of nephrotoxicity. Correct fluid deficits before or during treatment.
• Patients with cystic fibrosis: Altered pharmacokinetics (larger volume of distribution, faster clearance) mean that standard doses often produce subtherapeutic levels; higher milligram-per-kilogram doses are usually required under specialist guidance.
• Patients with neuromuscular disease: Myasthenia gravis, Parkinson disease, and similar conditions increase the risk of neuromuscular blockade. Tobramycin should be avoided if possible.
• Patients with burns, obesity, or septic shock: These conditions alter volume of distribution and clearance; individualised, level-guided dosing is essential.
• Neonates, infants, and children: Renal maturation affects clearance; weight-based and postmenstrual-age-based dosing with level monitoring is standard.

Pregnancy and Breastfeeding

Tobramycin crosses the placenta and has been associated with irreversible bilateral congenital deafness in infants exposed in utero, a risk well documented for streptomycin and kanamycin and assumed to apply to all systemic aminoglycosides. It should therefore be used during pregnancy only when there is no safer therapeutic alternative for a serious or life-threatening infection. When tobramycin must be used, the lowest effective dose and shortest duration should be chosen, therapeutic drug monitoring is mandatory, and the newborn should undergo audiological assessment.

Tobramycin is excreted into breast milk at low concentrations. Because oral bioavailability is negligible in healthy term infants, systemic exposure through breastfeeding is generally low; however, disruption of the infant’s gut flora and the theoretical possibility of sensitisation mean the decision to continue breastfeeding during therapy should be individualised in consultation with the treating physician and paediatrician.

Driving and Operating Machinery

Dizziness, vertigo, and vestibular disturbance can occur with tobramycin and may impair the ability to drive, cycle, or operate machinery. Patients who experience these symptoms should not drive until they resolve and should seek medical advice promptly.

Important Information About Excipients

How Does Tobramycin EQL Pharma Interact with Other Drugs?

Because tobramycin shares elimination pathways and toxicity profiles with several commonly co-prescribed medicines, clinicians should review the full medication list at every dose adjustment. The following table summarises the most clinically relevant interactions.

Major Interactions

Other Relevant Interactions

Always give your healthcare team a complete list of current medicines, including over-the-counter analgesics, herbal products, and dietary supplements, before tobramycin is started. Do not discontinue or adjust the dose of any medicine without medical advice, as abrupt changes can destabilise the underlying condition being treated.

What Is the Correct Dosage of Tobramycin EQL Pharma?

Dosing decisions should always be made by a clinician with access to the patient’s weight, renal function, underlying diagnosis, and local antibiotic protocols. The following guidance summarises widely accepted dosing regimens drawn from the EMA summary of product characteristics, the British National Formulary, and IDSA guidelines. Individual hospitals may have local dosing and monitoring protocols that should be followed preferentially.

Adults

In adults with normal renal function, the prevailing approach in most hospitals is extended-interval (once-daily) dosing, most commonly 5 to 7 mg/kg of ideal body weight given as a slow intravenous infusion over 30 to 60 minutes, once every 24 hours. This strategy takes advantage of the concentration-dependent killing of aminoglycosides and allows a period of low serum concentration between doses, during which the drug washes out of renal tubular cells and cochlear hair cells. Multiple-daily dosing (typically 1 to 1.7 mg/kg every 8 hours) remains appropriate for selected indications where extended-interval dosing is not recommended, including infective endocarditis, pregnancy, extensive burns, ascites, severe obesity, and some paediatric indications. Ideal (rather than total) body weight is usually used for dose calculation in overweight and obese patients, because tobramycin distributes poorly into adipose tissue.

Children

Paediatric dosing is individualised by age and weight. A commonly used range for children aged 1 month to 12 years is 6 to 7.5 mg/kg/day, administered in three to four divided doses or once daily according to the local protocol and the indication. Therapeutic drug monitoring is particularly important in children because of variable volumes of distribution and immature renal function. Children with cystic fibrosis typically require higher doses because of enhanced clearance and expanded volume of distribution.

Neonates

In neonates, tobramycin dosing is determined primarily by gestational age and postnatal age, reflecting renal maturation. Typical regimens use 4 to 5 mg/kg every 24 to 36 hours in term infants during the first week of life, with adjustment based on trough or random serum levels. Preterm infants often require longer intervals. All neonatal aminoglycoside dosing should follow a validated local protocol, with pharmacy review and level monitoring.

Elderly

No fixed age-based dose reduction is recommended, but the elderly often have a lower glomerular filtration rate than serum creatinine alone would suggest. Dose calculations should use an estimated or measured creatinine clearance (for example, the Cockcroft-Gault equation or a validated eGFR formula) rather than relying on serum creatinine in isolation. Older patients are at particularly high risk of nephrotoxicity and ototoxicity, so shorter courses, level monitoring, and avoidance of concurrent nephrotoxins are especially important.

Therapeutic Drug Monitoring

Because of tobramycin’s narrow therapeutic window, measurement of serum tobramycin concentrations is considered standard of care, particularly after the second or third dose and whenever renal function, dose, or interval changes. Typical targets are shown below (local laboratory ranges should always be followed):

Missed Dose

Tobramycin is administered only in hospital or under qualified clinical supervision, so missed doses are uncommon. If a dose is missed or delayed, contact the treating team promptly. In most cases the next dose is simply given at the scheduled time; doses should not be doubled, because the peak concentration would rise into the toxic range and increase the risk of kidney and ear damage.

Overdose

Acute overdose of tobramycin can produce rapidly developing renal impairment, ototoxicity, and neuromuscular blockade. There is no specific antidote. Management is supportive and includes aggressive hydration and correction of electrolyte disturbances, continuous monitoring of renal function and hearing, and, in severe cases, extracorporeal removal by haemodialysis or, less effectively, haemofiltration. In the event of neuromuscular blockade and respiratory compromise, mechanical ventilation, intravenous calcium, and anticholinesterase agents (neostigmine) may be required.

What Are the Side Effects of Tobramycin EQL Pharma?

As with all medicines, tobramycin can cause side effects, although not everyone experiences them. The risk and severity of adverse effects correlate strongly with the total dose, the duration of therapy, the patient’s baseline kidney function and age, and the presence of concomitant nephrotoxic or ototoxic drugs. Because tobramycin is used almost exclusively to treat severe infections, distinguishing drug-related adverse events from complications of the underlying illness requires careful clinical judgement.

Side Effects by Frequency

Nephrotoxicity in More Detail

Nephrotoxicity occurs in an estimated 10 to 20 percent of patients receiving conventional-interval aminoglycoside therapy for more than a few days, although the incidence is lower with extended-interval dosing, short courses, and vigilant monitoring. Typical features include a progressive rise in serum creatinine, non-oliguric acute tubular necrosis, reduced urinary concentrating ability, and electrolyte wasting. Most cases are reversible after the drug is stopped, but recovery may take days to weeks and occasionally requires temporary dialysis. The risk is magnified by dehydration, advanced age, higher trough levels, longer treatment courses, and concomitant nephrotoxins. Strategies to minimise nephrotoxicity include using extended-interval dosing where appropriate, ensuring good hydration, correcting hypokalaemia and hypomagnesaemia, limiting duration, and reviewing all co-prescribed nephrotoxins.

Ototoxicity in More Detail

Aminoglycoside ototoxicity results from the selective accumulation of drug in cochlear hair cells (producing hearing loss) and vestibular hair cells (producing dizziness, vertigo, and unsteadiness). Early high-frequency hearing loss is often asymptomatic and only detectable by audiometry; once clinical deafness is apparent, damage is usually irreversible. Vestibular toxicity may persist as oscillopsia and chronic imbalance. Genetic susceptibility, particularly mitochondrial 12S rRNA variants (m.1555A>G and m.1494C>T), markedly increases the risk, and family history of aminoglycoside-induced deafness should prompt genetic testing and avoidance whenever possible. Any change in hearing, balance, or ear symptoms during or after tobramycin treatment must be reported immediately, because prompt drug cessation and audiological referral offer the best chance of preserving function.

How Should You Store Tobramycin EQL Pharma?

Correct storage and handling of Tobramycin EQL Pharma are essential to preserve sterility, chemical stability, and therapeutic potency. As a parenteral aminoglycoside formulation, tobramycin is sensitive to heat and prolonged exposure to light, and once the vial has been opened the solution must be considered a sterile product with a limited shelf life.

• Storage temperature: Store at room temperature, not above 25 °C (77 °F). Keep the vial in the outer carton to protect from light. Check the local summary of product characteristics for the exact storage instructions on your batch.
• Do not freeze: Freezing can damage the solution and its primary packaging. If the product has been frozen, it should be discarded.
• Single-use: Each vial is intended for single use only. Any solution remaining after withdrawing the dose must be discarded in accordance with local policies.
• Diluted solution: After dilution in 0.9% sodium chloride or 5% glucose, the solution should be used immediately. If storage before administration cannot be avoided, refrigerated storage (2 to 8 °C) for a short period may be acceptable, but the product should be used within 24 hours and never frozen; local pharmacy policies apply.
• Compatibility: Tobramycin solutions are compatible with standard IV administration sets. They are not compatible with heparin in the same syringe, and they must not be mixed with beta-lactam antibiotics in the same infusion bag or Y-site.
• Visual inspection: Before use, inspect the solution for particles or discolouration. Use only clear, colourless to slightly yellowish solutions. Any cloudy, particulate, or discoloured product must be discarded.
• Expiry date: Do not use after the expiry date printed on the carton and vial. The expiry date refers to the last day of the stated month.
• Safe disposal: Unused or expired medicines must not be disposed of via wastewater or household waste. Return unused product to a pharmacy or follow local pharmaceutical waste disposal rules to protect the environment.
• Keep out of reach of children: Although the medicine is administered in a supervised clinical setting, parents and caregivers should still ensure that any medicine in their environment is kept safely out of sight and reach of children.

Dilution and Preparation (Healthcare Professionals)

For intravenous infusion, the calculated dose of Tobramycin EQL Pharma 40 mg/ml should normally be diluted in 50 to 100 ml of 0.9% sodium chloride or 5% glucose and infused over 20 to 60 minutes. The infusion rate should not be faster than 20 minutes in order to avoid neuromuscular blockade. In fluid-restricted patients (such as infants), smaller volumes may be used under pharmacy guidance. Tobramycin should not be mixed in the same infusion as penicillins or cephalosporins because of in vitro inactivation; when both agents are required, they should be administered sequentially through separate lines or with an adequate flush between. Intramuscular administration is feasible for the 40 mg/ml concentration, but the intravenous route is preferred in seriously ill, shocked, or bleeding-prone patients.

What Does Tobramycin EQL Pharma Contain?

Understanding the complete composition of Tobramycin EQL Pharma is particularly important for patients who have known allergies or intolerances to specific excipients, including sulfite-sensitive individuals and patients with asthma. The following breakdown reflects the typical composition of a tobramycin 40 mg/ml parenteral solution; the specific excipients for an individual batch are printed on the carton and in the package leaflet provided by the manufacturer.

Active Substance

The active substance is tobramycin, supplied as tobramycin sulfate. Each millilitre of solution contains 40 mg of tobramycin. A 2 ml vial therefore contains 80 mg of tobramycin, and a larger 40 mg/ml presentation may contain different total volumes according to the specific pack size authorised in a particular country.

Other Ingredients (Excipients)

Typical excipients in a tobramycin 40 mg/ml injectable solution include:

• Sodium metabisulfite (E223) — antioxidant stabiliser; may rarely cause severe allergic reactions and bronchospasm in susceptible individuals, particularly asthmatics.
• Edetate disodium (EDTA) — chelating agent used to stabilise the active ingredient.
• Phenol or another approved antimicrobial preservative (formulation-dependent) to maintain sterility of the solution.
• Sulfuric acid and/or sodium hydroxide — for pH adjustment.
• Water for injections — solvent vehicle.

Appearance and Packaging

Tobramycin EQL Pharma is a clear, colourless to slightly yellowish aqueous solution supplied in glass vials. Pack sizes depend on the authorisation in each market and typically include single-vial cartons or multi-vial hospital packs. Tobramycin EQL Pharma is manufactured and marketed by EQL Pharma AB and is distributed to hospitals and pharmacies under national prescription-only regulations.

Because excipient lists, pack sizes, and presentations may vary by country and revision, always consult the most recent package leaflet and summary of product characteristics for the version of Tobramycin EQL Pharma used in your country.

References

This article is based on evidence from internationally recognised medical sources. All information has been reviewed for accuracy against current clinical guidelines and peer-reviewed research.

1. European Medicines Agency (EMA). Summary of Product Characteristics: Tobramycin 40 mg/ml solution for injection. Last updated 2025. Available at: European Medicines Agency.
2. U.S. Food and Drug Administration (FDA). Tobramycin Sulfate Injection — Prescribing Information. Revised 2024. Available at: fda.gov.
3. World Health Organization (WHO). WHO Model List of Essential Medicines – 23rd List (2023). Tobramycin is listed as an essential medicine for serious infections.
4. British National Formulary (BNF). Tobramycin. National Institute for Health and Care Excellence (NICE). Available at: bnf.nice.org.uk.
5. Drusano GL, Ambrose PG, Bhavnani SM, et al. Back to the future: using aminoglycosides again and how to dose them optimally. Clin Infect Dis. 2007;45(6):753-760. doi:10.1086/520991
6. Nicolau DP, Freeman CD, Belliveau PP, et al. Experience with a once-daily aminoglycoside program administered to 2,184 adult patients. Antimicrob Agents Chemother. 1995;39(3):650-655.
7. Prayle A, Watson A, Fortnum H, Smyth A. Side effects of aminoglycosides on the kidney, ear and balance in cystic fibrosis. Thorax. 2010;65(7):654-658.
8. Lortholary O, Tod M, Cohen Y, Petitjean O. Aminoglycosides. Med Clin North Am. 1995;79(4):761-787.
9. Smyth AR, Bhatt J. Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis. Cochrane Database Syst Rev. 2017;3:CD002009.
10. Rybak MJ, Abate BJ, Kang SL, et al. Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity. Antimicrob Agents Chemother. 1999;43(7):1549-1555.
11. Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications. Circulation. 2015;132(15):1435-1486.
12. Flume PA, Mogayzel PJ Jr, Robinson KA, et al. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. Am J Respir Crit Care Med. 2009;180(9):802-808.
13. Prezant TR, Agapian JV, Bohlman MC, et al. Mitochondrial ribosomal RNA mutation associated with both antibiotic-induced and non-syndromic deafness. Nat Genet. 1993;4(3):289-294.

Medical Editorial Team

This article was written and reviewed by the iMedic Medical Editorial Team, which includes board-certified physicians specialising in infectious diseases, clinical pharmacology, intensive care medicine, and hospital pharmacy. Our team follows international editorial standards and the GRADE evidence framework to ensure all medical information is accurate, current, and evidence-based.

Last reviewed: February 4, 2026 | Next scheduled review: August 4, 2026